<DOC>
	<DOCNO>NCT00763932</DOCNO>
	<brief_summary>This extension study monitor long-term safety efficacy rhGAA treatment patient infantile-onset Pompe disease previously treat rhGAA derive Synpac cell line</brief_summary>
	<brief_title>Extension Study Long-term Safety Efficacy Myozyme Patients With Pompe Disease Who Were Previously Enrolled Genzyme Sponsored Enzyme Replacement Therapy ( ERT ) Studies</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>The patient enrol Protocol AGLU00801 , AGLU00902 , AGLU01502 The patient 's legal guardian ( ) provide write informed consent prior study related procedure perform The patient his/her guardian ( ) able comply clinical protocol , require extensive clinical evaluation extend period time . Patients exclude study meet specific inclusion criterion , patient experience unmanageable AE Protocol AGLU00801 , AGLU00902 , AGLU01502 ( determine agree upon Principal Investigator Genzyme Corporation ) , due Synpac rhGAA therapy , would preclude continue therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>